Literature DB >> 34794001

Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.

Stephanie Wilt1, Sean Kodani2, Leah Valencia1, Paula K Hudson1, Stephanie Sanchez3, Taylor Quintana3, Christophe Morisseau2, Bruce D Hammock2, Ram Kandasamy4, Stevan Pecic5.   

Abstract

Fatty acid amide hydrolase (FAAH) is a membrane protein that hydrolyzes endocannabinoids, and its inhibition produces analgesic and anti-inflammatory effects. The soluble epoxide hydrolase (sEH) hydrolyzes epoxyeicosatrienoic acids (EETs) to dihydroxyeicosatetraenoic acids. EETs have anti-inflammatory and inflammation resolving properties, thus inhibition of sEH consequently reduces inflammation. Concurrent inhibition of both enzymes may represent a novel approach in the treatment of chronic pain. Drugs with multiple targets can provide a superior therapeutic effect and a decrease in side effects compared to ligands with single targets. Previously, microwave-assisted methodologies were employed to synthesize libraries of benzothiazole analogs from which high affinity dual inhibitors (e.g. 3, sEH IC50 = 9.6 nM; FAAH IC50 = 7 nM) were identified. Here, our structure-activity relationship studies revealed that the 4-phenylthiazole moiety is well tolerated by both enzymes, producing excellent inhibition potencies in the low nanomolar range (e.g. 6o, sEH IC50 = 2.5 nM; FAAH IC50 = 9.8 nM). Docking experiments show that the new class of dual inhibitors bind within the catalytic sites of both enzymes. Prediction of several pharmacokinetic/pharmacodynamic properties suggest that these new dual inhibitors are good candidates for further in vivo evaluation. Finally, dual inhibitor 3 was tested in the Formalin Test, a rat model of acute inflammatory pain. The data indicate that 3 produces antinociception against the inflammatory phase of the Formalin Test in vivo and is metabolically stable following intraperitoneal administration in male rats. Further, antinociception produced by 3 is comparable to that of ketoprofen, a traditional nonsteroidal anti-inflammatory drug. The results presented here will help toward the long-term goal of developing novel non-opioid therapeutics for pain management.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  4-Phenylthiazole moiety; ADMET predictions; Docking experiments; Enzyme inhibition; Formalin test; Microwave-assisted synthesis; Polypharmacology; Structure-Activity Relationship study

Mesh:

Substances:

Year:  2021        PMID: 34794001      PMCID: PMC8900675          DOI: 10.1016/j.bmc.2021.116507

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  71 in total

1.  Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

Authors:  Stevan Pecic; Shi-Xian Deng; Christophe Morisseau; Bruce D Hammock; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2011-10-28       Impact factor: 2.823

Review 2.  Structure and function of fatty acid amide hydrolase.

Authors:  Michele K McKinney; Benjamin F Cravatt
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

3.  Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR.

Authors:  Maxim Totrov
Journal:  Chem Biol Drug Des       Date:  2007-12-07       Impact factor: 2.817

Review 4.  Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  K D Rainsford
Journal:  Am J Med       Date:  1999-12-13       Impact factor: 4.965

5.  Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive.

Authors:  Oscar Sasso; Karen Wagner; Christophe Morisseau; Bora Inceoglu; Bruce D Hammock; Daniele Piomelli
Journal:  Pharmacol Res       Date:  2015-04-14       Impact factor: 7.658

6.  CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain.

Authors:  N Clayton; F H Marshall; C Bountra; C T O'Shaughnessy
Journal:  Pain       Date:  2002-04       Impact factor: 6.961

Review 7.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

8.  The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.

Authors:  Tohru Takebe; Ryoka Imai; Shunsuke Ono
Journal:  Clin Transl Sci       Date:  2018-07-30       Impact factor: 4.689

9.  Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.

Authors:  Sean D Kodani; Debin Wan; Karen M Wagner; Sung Hee Hwang; Christophe Morisseau; Bruce D Hammock
Journal:  ACS Omega       Date:  2018-10-25

10.  The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition.

Authors:  Giulia Palermo; Angelo D Favia; Marino Convertino; Marco De Vivo
Journal:  ChemMedChem       Date:  2015-11-23       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.